Mesalazine

What is Mesalazine?

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a non-systemic anti-inflammatory medication used primarily in the treatment of inflammatory bowel disease (IBD). It belongs to the aminosalicylate drug class and is classified under ATC code A07, which encompasses agents used for bowel disorders. Mesalazine was first developed in the 1970s as a targeted therapeutic agent for conditions affecting the gastrointestinal tract, building upon the earlier use of sulfasalazine.

Mesalazine works locally within the colon and small intestine, delivering its therapeutic effects directly to the sites of inflammation. Unlike its predecessor sulfasalazine, Mesalazine does not contain a sulfonamide component, making it suitable for patients with sulfa allergies. The medication is available in multiple formulations including immediate-release tablets, delayed-release tablets, extended-release capsules, and rectal preparations such as enemas and suppositories, allowing flexible treatment options based on disease location and severity.

The pharmaceutical profile of Mesalazine makes it a cornerstone therapy for maintaining remission in ulcerative colitis and managing mild to moderate Crohn's disease. Its efficacy and tolerability have been well-documented through decades of clinical use and numerous controlled trials, establishing it as a first-line agent for IBD management in many treatment guidelines worldwide.

⚙️ Mechanism of Action

Mesalazine exerts its therapeutic effects through multiple anti-inflammatory pathways at the cellular and molecular level. The medication acts as a topical anti-inflammatory agent when it comes into direct contact with the inflamed mucosa of the gastrointestinal tract. Its mechanism involves the inhibition of prostaglandin and leukotriene production, which are key inflammatory mediators responsible for the pathology of inflammatory bowel disease. By reducing the synthesis of these chemical messengers, Mesalazine effectively dampens the inflammatory cascade that characterizes IBD.

• Inhibits prostaglandin and leukotriene synthesis by modulating arachidonic acid metabolism in intestinal epithelial cells and immune cells
• Reduces production of tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines that drive intestinal inflammation
• Suppresses activation and proliferation of intestinal T-lymphocytes and other immune cells infiltrating the affected mucosa
• Acts as a free radical scavenger, neutralizing reactive oxygen species (ROS) that contribute to oxidative damage in inflamed tissues
• Stabilizes intestinal epithelial tight junctions, improving the intestinal barrier function and reducing bacterial translocation

🏥 Medical Uses & Indications

Mesalazine is a versatile therapeutic agent with well-established indications for various gastrointestinal inflammatory conditions. Its primary use remains in the management of inflammatory bowel disease, where it serves both as an induction agent for active disease and as a maintenance therapy to prevent relapse. The drug's ability to deliver its anti-inflammatory effects directly to the affected areas of the intestine makes it particularly valuable for treating localized inflammation while minimizing systemic side effects.

Primary Indications

• Ulcerative Colitis: Induction of remission and maintenance therapy for mild to moderate disease, including both left-sided colitis and pancolitis
• Crohn's Disease: Treatment of mild to moderate disease activity, particularly in patients with colonic involvement or ileo-colonic disease
• Pouchitis: Inflammation of the ileal pouch created during restorative proctocolectomy, commonly seen in patients with ulcerative colitis history
• Proctitis and Proctosigmoiditis: Localized inflammation of the rectum and sigmoid colon, particularly responsive to rectal formulations
• Maintenance of Remission: Long-term prevention of disease relapse in both ulcerative colitis and Crohn's disease, reducing the need for corticosteroid therapy
• Acute Flares: Induction therapy for active inflammatory episodes, often combined with corticosteroids or other immunosuppressive agents in moderate to severe cases

Secondary / Off-label Uses

• Celiac Disease: Adjunctive therapy in select cases where gastrointestinal inflammation persists despite strict gluten avoidance
• Microscopic Colitis: Management of collagenous colitis and lymphocytic colitis subtypes
• Irritable Bowel Syndrome: Limited evidence suggests potential benefit in IBS with concurrent intestinal inflammation
• Behçet's Disease: Rare indication for management of gastrointestinal manifestations associated with this systemic vasculitis

💊 Dosage & Administration

Mesalazine dosing must be individualized based on the disease indication, severity, location of inflammation, and patient-specific factors including age and weight. Different formulations offer flexibility in dosing and administration routes. Delayed-release formulations are typically used for small bowel and ileocecal disease, while extended-release formulations target the colon. Rectal preparations deliver high local concentrations to the distal colon and rectum. Treatment duration varies from acute induction therapy (typically 4-12 weeks) to indefinite maintenance therapy for disease prevention.

Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Some patients benefit from combination therapy with rectal and oral formulations for synergistic effect. Therapeutic response may take 2-4 weeks, and dose adjustments should be made gradually under medical supervision.

⚠️ Side Effects

Common Side Effects (>10% of patients)

• Gastrointestinal disturbances including nausea, abdominal pain, and diarrhea, which may be difficult to distinguish from disease activity
• Headache and dizziness, typically mild and transient
• Dyspepsia and flatulence related to altered gut microbiota and fermentation of unabsorbed drug
• Loss of appetite and mild weight loss in some patients
• Rash or pruritus affecting the skin, usually mild and self-limited
• Fatigue and malaise, particularly during initial treatment phase

Less Common Side Effects (1-10%)

• Elevated liver enzymes (AST, ALT) requiring periodic monitoring, usually reversible upon discontinuation
• Hematologic changes including thrombocytopenia, leukopenia, or hemolytic anemia in susceptible individuals
• Allergic reactions ranging from mild urticaria to severe anaphylaxis in hypersensitive patients
• Pancreatitis presenting with epigastric pain, elevated amylase, and lipase levels
• Exacerbation of colitis paradoxically occurring in rare instances despite therapeutic intent

Rare but Serious Side Effects

• Nephrotoxicity: Acute interstitial nephritis or other renal injury with elevated creatinine and proteinuria, potentially irreversible if not recognized early
• Hepatotoxicity: Fulminant hepatitis or cirrhosis, though extremely rare, requiring immediate discontinuation and hepatic assessment
• Cardiac Effects: Myocarditis and pericarditis reported rarely, presenting with chest pain, dyspnea, and ECG changes requiring urgent cardiology evaluation

🔄 Drug Interactions

Mesalazine has a favorable drug interaction profile due to its primarily local mechanism of action and minimal systemic absorption. However, certain interactions warrant clinical attention, particularly with medications affecting renal function, those competing for renal tubular secretion, or agents that alter intestinal pH and drug absorption. Regular monitoring of renal function and blood counts is recommended during concurrent use of potentially interactive medications.

• Azathioprine and 6-Mercaptopurine: Concurrent use may increase risk of myelosuppression and bone marrow toxicity; hematologic monitoring is essential
• ACE Inhibitors and NSAIDs: These agents may potentiate nephrotoxicity risk when combined with Mesalazine; renal function should be monitored closely
• Warfarin and Anticoagulants: Mesalazine may affect anticoagulant metabolism; INR monitoring is recommended with dose adjustments as needed
• Sulfasalazine: Concurrent administration is not recommended due to overlapping mechanisms and potential for additive toxicity and adverse effects
• Methotrexate: May increase risk of methotrexate-related toxicity; concurrent use requires careful monitoring and potential dose adjustment
• Antibiotics: Certain antibiotics may alter intestinal absorption of Mesalazine; timing of administration should be considered

🚫 Contraindications & Warnings

• Severe Renal Impairment: Mesalazine should be avoided in patients with eGFR less than 30 mL/min/1.73m² due to increased risk of nephrotoxicity and drug accumulation
• Hypersensitivity to Aminosalicylates: Patients with documented allergy to Mesalazine, salicylates, or other aminosalicylate compounds should not receive this medication
• Acute Severe Colitis: In fulminant disease with toxic megacolon or perforation risk, Mesalazine alone is insufficient and should be combined with systemic corticosteroids or other aggressive interventions
• Cardiovascular Disease: Caution is warranted in patients with pre-existing myocarditis, pericarditis, or significant cardiac arrhythmias
• Hepatic Disease: Patients with cirrhosis or moderate to severe hepatic impairment require careful monitoring; dose adjustment may be necessary
• Pregnancy and Lactation: While generally considered safe in pregnancy with data supporting fetal benefit, individual risk-benefit assessment is essential; Mesalazine is excreted in breast milk in small amounts

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. The content provided does not replace professional medical advice, diagnosis, or treatment. Individual patient factors, comorbidities, and clinical context must be considered by healthcare providers when making treatment decisions.

❓ Frequently Asked Questions

Is Mesalazine safe for long-term use?

Yes, Mesalazine has an excellent safety profile for long-term maintenance therapy in inflammatory bowel disease, with millions of patient-years of clinical experience supporting its chronic use. However, periodic monitoring of renal function (serum creatinine, eGFR) and complete blood counts is recommended every 6-12 months to detect early signs of nephrotoxicity or hematologic abnormalities. Patients should maintain regular follow-up with their gastroenterologist, and any concerning symptoms warrant prompt medical evaluation.

Can Mesalazine be taken with food?

The interaction between food and Mesalazine absorption depends on the specific formulation. Immediate-release tablets should ideally be taken on an empty stomach or with a small amount of food to optimize absorption. Delayed-release and extended-release formulations are designed to be pH-dependent and should not be crushed or chewed; they can be taken with meals without significant impact on efficacy. Rectal preparations should ideally be administered after bowel movement to maximize contact time with inflamed mucosa. Always follow specific formulation instructions provided by your pharmacist.

What should I do if I miss a dose?

If you miss a dose of Mesalazine, take it as soon as you remember unless it is nearly time for your next scheduled dose. Do not double-dose to make up for a missed dose, as this increases the risk of adverse effects. For rectal preparations, a missed nighttime dose can typically be administered the following evening. Maintain as consistent a dosing schedule as possible for optimal disease control. If you frequently miss doses, discuss medication timing or formulation alternatives with your healthcare provider to improve adherence.